South Korean drugmaker JW Pharmaceutical is partnering with US-based Tempus AI to speed up cancer drug development using artificial intelligence and lab-grown tumor models.
The Seoul-based company will tap into Tempus’s database of clinical records and pathology images, combining them with miniature organ models grown from patient tissue samples. These organoids will help evaluate potential new treatments before moving to costly human trials.
The collaboration marks JW Pharmaceutical’s push to modernize its research approach as competition in oncology drug development intensifies. By comparing lab results with real patient outcomes, the company aims to better predict which compounds are likely to succeed in clinical testing.
Tempus will provide tumor samples and genomic analysis technology to create detailed profiles of cancer patients. The Chicago-based firm has built one of healthcare’s largest clinical and molecular data platforms since its 2015 founding.
JW Pharmaceutical’s chief technology officer Park Chan-hee said the partnership represents a key shift in Korean drug development methods. The deal’s financial terms weren’t disclosed.
The collaboration reflects a growing trend of pharmaceutical companies using AI and patient-derived models to cut drug development costs and increase success rates in clinical trials.
